Interaction of estrogen receptor α with protein kinase C α and c-Src in osteoblasts during differentiation

Bone

Volumn 34, Issue 1, 2004, Pages 100-111

  Longo, Maurizio ^a,b   Brama, Marina ^a,b   Marino, Maria ^c   Bernardini, Silvia ^d   Korach, Kenneth S ^e   Wetsel, William C ^f   Scandurra, Roberto ^b   Faraggiana, Tullio ^g   Spera, Giovanni ^b   Baron, Roland ^h   Teti, Anna ^a   Migliaccio, Silvia ^a,b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ROMA TRE UNIVERSITY   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h YALE UNIVERSITY   (United States)

Author keywords

c Src; Differentiation; Estrogen receptor ; Osteoblast; PKC

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MEMBRANE ENZYME; PROTEIN KINASE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ZETA; PROTEIN P60; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HORMONE RESPONSE; IMMUNOPRECIPITATION; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PROTEIN VARIANT; RAT;

EID: 0942289887     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.09.007     Document Type: Article

References (50)

1. Riggs B.L., Melton L.J. Evidence for two distinct syndromes of involutional osteoporosis. Am. J. Med. 75:1983;899-901.
2. Ankrom M.A., Patterson J.A., d'Avis P.Y., Vetter U.K., Blackman M.R., Sponseller P.D.et al. Age-related changes in human oestrogen receptor alpha functions and levels in osteoblasts. Biochem. J. 333:1998;787-794.
3. Migliaccio S., Wetsel W.C., William M.F., Washburn T.F., Korach K.S. Endogenous protein kinase C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels. Mol. Endocrinol. 7:1993;1133-1143.
4. Ignar-Trowbridge D.M., Nelson K.G., Bidwell M.C., Curtis S.W., Washburn T.F., McLachlan J.A.et al. Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 89:1992;4658-4662.
5. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activation protein kinase. Science. 270:1995;1491-1494.
6. Curtis S.W., Washburn T.F., Sewall C., DiAgustine R., Lindzey J., Couse J.F.et al. Physiological coupling of growth factor and steroid signaling pathways: estrogen receptor knockout mice lack estrogen-like response to EGF. Proc. Natl. Acad. Sci. U. S. A. 93:1996;12626-12630.
7. Ways D.K., Kukoly C.A., DeVente J., Hooker J.L., Winifred O.B., Posekany K.J.et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95:1995;1906-1915.
8. Dekker L.V., Parker P.J. Protein kinase C - A question of specificity. TIBS. 19:1994;73-77.
9. Hofmann J. The potential for isoenzyme selective modulation of protein kinase C. FASEB J. 11:1997;649-669.
10. Hug H., Sarre T.F. Protein kinase C isoenzymes: divergence in signal transduction? Biochem. J. 291:1993;329-343.
11. Way K.J., Chou E., King G.L. Identification of PKC-isoform-specific biological actions using pharmacological approaches. TIPS. 21:2000;181-187.
12. Murray N.R., Baumgardner G.P., Burns D.J., Fields A.P. Protein kinase C isotypes in human erytroleukemia (K562) cell proliferation and differentiation. J. Biol. Chem. 268:1993;15847-15853.
13. Mischak H., Pierce J.H., Goodnight J.A., Kazanietz M.G., Blumberg P.M., Muschinski J.F. Phorbol-ester induced myeloid differentiation is mediated by protein kinase C-α and -δ and not by protein kinase C-βII, -ε, -ζ and -θ J. Biol. Chem. 268:1993;20110-20115.
14. Fragale A., Tartaglia M., Bernardini S., Di Stasi M., Di Rocco C., Velardi F.et al. Decreased proliferation and altered differentiation in osteoblast from genetically and clinically distinct craniosynostotic disorders. Am. J. Pathol. 154:1999;1465-1477.
15. Debiais F., Lemonnier J., Hay E., Caverzasio J., Marie P.J. Stimulation of N-cadherin expression by fibroblast growth factor-2 (FGF-2) in human calvaria osteoblastic cells requires PKCα and β and src-kinase pathways. Bone. 26:2000;1S-25S.
16. Lemonnier J., Hay E., Modrowski D., Delannoy P., Lomri A., Caverzasio J.et al. PKC-α is involved in the increased expression of N-cadherin and osteoblast marker genes induced by the ser252trp FGFR2 mutation in Apert craniosynostoses. Bone. 26:2000;1S-25S.
17. Ree A.H., Landmark B.F., Walaas S.I., Lahooti H., Eilvar L., Eskild W.et al. Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptor by phorbol ester and calcium in MCF-7 cells. Endocrinology. 129:1991;339-344.
18. Tzukermann M., Zhang X.K., Pfahl M. Inhibition of estrogen receptor activity by the tumor promoter 12-0-tetradecanoylphorbol-13-acetate: a molecular analysis. Mol. Endocrinol. 5:1991;1983-1992.
19. Yudt M.R., Vorojeikina D., Zhong L., Skafar D.F., Sasson S., Gasiewick S.et al. Function of estrogen receptor tyrosine 537 in hormone binding DNA binding and transactivation. Biochemistry. 38:1999;14146-14156.
20. Zhang Q.X., Borg A., Wolf D.M., Oesterreich S., Fuqua S.A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57:1997;1244-1249.
21. Weis K.E., Ekena K., Thomas J.A., Lazennec G., Katzenellenbogen B.S. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol. 10:1996;1388-1398.
22. Wetsel W.C., Khan W.A., Merchenthaler I., Rivera H., Halpera A.E., Phung H.M.et al. Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J. Cell Biol. 117:1992;121-133.
23. Zang Q., Lu Z., Curto M., Barile N., Shalloway D., Foster D. Association between v-Src and protein kinase C δ in v-Src transformed fibroblasts. J. Biol. Chem. 272:1997;13275-13280.
24. Song J.S., Swann P.G., Szallasi Z., Blank U., Blumberg P.M., Rivera J. Tyrosine phosphorylation-dependent and-independent associations of protein kinase C-δ with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-delta. Oncogene. 16:1998;3357-3368.
25. Bilezikian J.P., Morishima A., Bell J., Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339:1998;599-603.
26. Korach K.S., Couse J.F., Curtis S.W., Washburn T.F., Lindzey J., Kimbro K.S.et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res. 51:1996;159-188.
27. Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., Piaseu N., Chailurkit T. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin. Endocrinol. 49:1998;803-809.
28. Martinez J., Fuentes M., Cambiazo V., Santibanez J.F. Bone extracellular matrix stimulates invasiveness of estrogen-responsive human mammary MCF-7 cells. Int. J. Cancer. 83:1999;278-282.
29. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer. 88:2000;892-898.
30. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-Src protooncogene leads to osteopetrosis in mice. Cell. 64:1991;693-702.
31. Marzia M., Sims N.A., Voit S., Migliaccio S., Taranta A., Bernardini S. et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151:2000;311-320.
32. Migliaccio S., Davis V.L., Gibson M.K., Gray T.K., Korach K.S. Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17/2.8) stably transfected with estrogen receptor. Endocrinology. 130:1992;2617-2624.
33. Robey P.G., Termine J.D. Human bone cells in vitro. Calcif. Tissue Int. 37:1985;453-460.
34. Wodgett G.R., Hunter T. Immunological evidence for two physiological forms of protein kinase C. Mol. Cell. Biol. 7:1987;85-96.
35. Robey P.G., Bianco P., Termine J.D. Disorders of bone and mineral metabolism. 1992;Raven Press, Philadelphia (NY).
36. Denger S., Reid G., Ko M., Flouriot G., Parsch D., Brand H.et al. ER gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol. Endocrinol. 15:2001;2064-2077.
37. Sanders J., Stern P. Expression and phorbol ester-induced down-regulation of protein kinase C isoenzymes in osteoblasts. J. Bone Miner. Res. 11:1996;1862-1872.
38. Takahashi M, Mukai H, Oishi K, Isagawa T, Ono Y. Association of immature hypo-phosphorylated protein kinase C ε with an anchoring protein CG-NAP. J Biol Chem 2000;275:34592-96, 423.
39. Migliaccio S., Washburn T.F., Fillo S., Rivera H., Teti A., Korach K.S. et al. Modulation of estrogen receptor levels in mouse uterus by protein kinase C isoenzymes. Endocrinology. 139:1998;4598-4606.
40. Sheila M.T., Brugge J.S. Cellular functions regulated by src family kinases. Annu. Rev. Cell Dev. Biol. 13:1997;513-609.
41. src at a novel site. Cell. 42:1985;849-857.
42. Eriksen E.F., Colvard D.S., Berg N.J., Graham M.L., Mann K.G., Spelsberg T.C.et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 241:1988;85-88.
43. Komm B.S., Terpening C.M., Benz D.J., Graeme K.A., Gallegos A., Korc M. et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 241:1988;81-84.
44. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G.et al. Identification of a new isoform of the human estrogen receptor-α (hERα) that is encoded by distinct transcripts and that is able to repress hERα activation function 1. EMBO J. 19:2000;4688-4700.
45. Black J.D. Protein kinase C-mediated regulation of the cell cycle. Front. Biosci. 5:2000;406.
46. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-613.
47. Feng W., Webb P., Nguyen P., Liu X., Li J., Karin M.et al. Potentiation of estrogen receptor activation function 1 (AF-1) by src/JNK through a serine 118-independent pathway. Mol. Endocrinol. 15:2001;32-45.
48. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L.et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104:2001;719-730.
49. Lu D., Giguere V. Requirement of Ras-dependent pathways for activation of the transforming growth factor β3 promoter by estradiol. Endocrinology. 142:2001;751-759.
50. Lemonnier J., Hay E., Delannoy P., Lomri A., Modrowski D., Caverzasio J.et al. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J. Bone Miner. Res. 16:2001;832-845.